Literature DB >> 19555856

Development and pathology of pulmonary hypertension.

Rubin M Tuder1, Steven H Abman2, Thomas Braun3, Frédérique Capron4, Troy Stevens5, Patricia A Thistlethwaite6, Sheila G Haworth7.   

Abstract

The Development and Pathology working group was charged with reviewing the present knowledge, gaps in understanding, and areas for further studies in a broad range of themes. These themes in pulmonary vascular biology and pathobiology involved: 1) pulmonary vascular development; 2) pulmonary vascular disease accompanying fetal development and perinatal life; 3) properties of pulmonary vascular endothelial cells; 4) role of bone marrow cells in pulmonary vascular disease; 5) insights into pulmonary thromboembolic disease; 6) role of pathology in the assessment of pulmonary vascular disease; and 7) considerations of tissue banking for research in pulmonary hypertension. These important goals provide a blueprint for future research that may significantly impact our present and future understanding of pulmonary hypertension.

Entities:  

Mesh:

Year:  2009        PMID: 19555856     DOI: 10.1016/j.jacc.2009.04.009

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  88 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

Review 2.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

3.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

4.  Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies.

Authors:  Kelley L Colvin; Patrick J Cripe; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

5.  Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.

Authors:  Gerry T M Wagenaar; Rozemarijn M A Sengers; El Houari Laghmani; Xueyu Chen; Melissa P H A Lindeboom; Anton J M Roks; Gert Folkerts; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

6.  Pulmonary Vascular Capacitance is Associated with Vasoreactivity and Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Xiao-Ling Cheng; Jian-Guo He; Zhi-Hong Liu; Qing Gu; Xin-Hai Ni; Zhi-Hui Zhao; Qin Luo; Chang-Ming Xiong
Journal:  Lung       Date:  2016-06-07       Impact factor: 2.584

7.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09

8.  Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.

Authors:  Nazzareno Galiè; Massimiliano Palazzini; Alessandra Manes
Journal:  Eur Heart J       Date:  2010-05-26       Impact factor: 29.983

9.  Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function.

Authors:  Steven Lammers; Devon Scott; Kendall Hunter; Wei Tan; Robin Shandas; Kurt R Stenmark
Journal:  Compr Physiol       Date:  2012-01-01       Impact factor: 9.090

10.  Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells.

Authors:  Hilary A White; Yi Jin; Louis G Chicoine; Bernadette Chen; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-02-10       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.